Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive ...

The phosphorylation of protein kinases leads to the activation of signal-transduction pathways, which have a critical role in a variety of biologic processes, including cell growth ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...

The combination demonstrated a tolerable safety profile, as per the trial’s preliminary data involving 16 subjects.

Arvinas, Pfizer announce initial phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combo with abemaciclib at 2024 SABC symposium: New Haven, Connecticut Thursday, Dec ...

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine ...

Results of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...

Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) announced preliminary data from the ongoing Phase 1b portion of the ...